Preclinical and clinical studies of bone marrow uptake of fluorine-18- fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy

Yoshifumi Sugawara, Susan J. Fisher, Kenneth R. Zasadny, Paul V. Kison, Laurence H. Baker, Richard L. Wahl

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the effect of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) on bone marrow glucose metabolism in rodents and in patients, as assessed by 2- [fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) uptake measured directly or by positron-emission tomography (PET) scanning. Materials and Methods: Groups of three rats received either daily saline, G-CSF, or GM-CSF injections far 7 days. After treatment, FDG was injected and F-18 activities in tissues measured 1 hour later. Twenty-two breast cancer patients treated with multiagent chemotherapy were sequentially studied with PET. Eleven patients received G-CSF therapy as an adjunct to chemotherapy, while 11 received chemotherapy only. The standardized uptake value-lean (SUL) of bone marrow FDG uptake was measured and compared. Results: In rats, bone marrow F-18 activity was significantly higher in both CSF groups than in the saline group (G-CSF, 0.44 ± 0.08; GM-CSF, 0.88 ± 0.02; saline, 0.18 ± 0.02% injected dose [ID]/g · kg; P <.05), but the other normal tissues had comparable biodistributions to controls. In breast cancer patients, the FDG uptake of bone marrow did not change with chemotherapy alone; however, marrow uptake was increased after treatment with G-CSF. The dose of G-CSF and duration of treatment were correlated with the extent of increase in FDG uptake. The SUL of bone marrow was as follows: baseline, 1.56 ± 0.23; after one cycle, 3.13 ± 1.40 (P <.01); after two cycles, 2.22 ± 0.85 (P <.05); and after three cycles, 2.14 ± 0.79 (P <.05), respectively. Although the FDG uptake of bone marrow declined after G-CSF treatment was completed, it was higher than the baseline level far up to 4 weeks post-completion of G-CSF and the elevated marrow FDG uptake was sustained longer than the period of blood neutrophil count elevation. Conclusion: Substantial increases in bone marrow FDG uptake are rapidly induced by CSF treatments and should not be misinterpreted as diffuse bone marrow metastases.

Original languageEnglish (US)
Pages (from-to)173-180
Number of pages8
JournalJournal of Clinical Oncology
Volume16
Issue number1
StatePublished - Jan 1998
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Granulocyte Colony-Stimulating Factor
Deoxyglucose
Bone Marrow
Drug Therapy
Granulocyte-Macrophage Colony-Stimulating Factor
Positron-Emission Tomography
Therapeutics
Clinical Studies
Breast Neoplasms
Fluorine
Rodentia
Neutrophils
Neoplasm Metastasis
Glucose
Injections

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Preclinical and clinical studies of bone marrow uptake of fluorine-18- fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. / Sugawara, Yoshifumi; Fisher, Susan J.; Zasadny, Kenneth R.; Kison, Paul V.; Baker, Laurence H.; Wahl, Richard L.

In: Journal of Clinical Oncology, Vol. 16, No. 1, 01.1998, p. 173-180.

Research output: Contribution to journalArticle

Sugawara, Yoshifumi ; Fisher, Susan J. ; Zasadny, Kenneth R. ; Kison, Paul V. ; Baker, Laurence H. ; Wahl, Richard L. / Preclinical and clinical studies of bone marrow uptake of fluorine-18- fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 1. pp. 173-180.
@article{81aca90c5de443dfa440b3fb6b781063,
title = "Preclinical and clinical studies of bone marrow uptake of fluorine-18- fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy",
abstract = "Purpose: To evaluate the effect of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) on bone marrow glucose metabolism in rodents and in patients, as assessed by 2- [fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) uptake measured directly or by positron-emission tomography (PET) scanning. Materials and Methods: Groups of three rats received either daily saline, G-CSF, or GM-CSF injections far 7 days. After treatment, FDG was injected and F-18 activities in tissues measured 1 hour later. Twenty-two breast cancer patients treated with multiagent chemotherapy were sequentially studied with PET. Eleven patients received G-CSF therapy as an adjunct to chemotherapy, while 11 received chemotherapy only. The standardized uptake value-lean (SUL) of bone marrow FDG uptake was measured and compared. Results: In rats, bone marrow F-18 activity was significantly higher in both CSF groups than in the saline group (G-CSF, 0.44 ± 0.08; GM-CSF, 0.88 ± 0.02; saline, 0.18 ± 0.02{\%} injected dose [ID]/g · kg; P <.05), but the other normal tissues had comparable biodistributions to controls. In breast cancer patients, the FDG uptake of bone marrow did not change with chemotherapy alone; however, marrow uptake was increased after treatment with G-CSF. The dose of G-CSF and duration of treatment were correlated with the extent of increase in FDG uptake. The SUL of bone marrow was as follows: baseline, 1.56 ± 0.23; after one cycle, 3.13 ± 1.40 (P <.01); after two cycles, 2.22 ± 0.85 (P <.05); and after three cycles, 2.14 ± 0.79 (P <.05), respectively. Although the FDG uptake of bone marrow declined after G-CSF treatment was completed, it was higher than the baseline level far up to 4 weeks post-completion of G-CSF and the elevated marrow FDG uptake was sustained longer than the period of blood neutrophil count elevation. Conclusion: Substantial increases in bone marrow FDG uptake are rapidly induced by CSF treatments and should not be misinterpreted as diffuse bone marrow metastases.",
author = "Yoshifumi Sugawara and Fisher, {Susan J.} and Zasadny, {Kenneth R.} and Kison, {Paul V.} and Baker, {Laurence H.} and Wahl, {Richard L.}",
year = "1998",
month = "1",
language = "English (US)",
volume = "16",
pages = "173--180",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Preclinical and clinical studies of bone marrow uptake of fluorine-18- fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy

AU - Sugawara, Yoshifumi

AU - Fisher, Susan J.

AU - Zasadny, Kenneth R.

AU - Kison, Paul V.

AU - Baker, Laurence H.

AU - Wahl, Richard L.

PY - 1998/1

Y1 - 1998/1

N2 - Purpose: To evaluate the effect of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) on bone marrow glucose metabolism in rodents and in patients, as assessed by 2- [fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) uptake measured directly or by positron-emission tomography (PET) scanning. Materials and Methods: Groups of three rats received either daily saline, G-CSF, or GM-CSF injections far 7 days. After treatment, FDG was injected and F-18 activities in tissues measured 1 hour later. Twenty-two breast cancer patients treated with multiagent chemotherapy were sequentially studied with PET. Eleven patients received G-CSF therapy as an adjunct to chemotherapy, while 11 received chemotherapy only. The standardized uptake value-lean (SUL) of bone marrow FDG uptake was measured and compared. Results: In rats, bone marrow F-18 activity was significantly higher in both CSF groups than in the saline group (G-CSF, 0.44 ± 0.08; GM-CSF, 0.88 ± 0.02; saline, 0.18 ± 0.02% injected dose [ID]/g · kg; P <.05), but the other normal tissues had comparable biodistributions to controls. In breast cancer patients, the FDG uptake of bone marrow did not change with chemotherapy alone; however, marrow uptake was increased after treatment with G-CSF. The dose of G-CSF and duration of treatment were correlated with the extent of increase in FDG uptake. The SUL of bone marrow was as follows: baseline, 1.56 ± 0.23; after one cycle, 3.13 ± 1.40 (P <.01); after two cycles, 2.22 ± 0.85 (P <.05); and after three cycles, 2.14 ± 0.79 (P <.05), respectively. Although the FDG uptake of bone marrow declined after G-CSF treatment was completed, it was higher than the baseline level far up to 4 weeks post-completion of G-CSF and the elevated marrow FDG uptake was sustained longer than the period of blood neutrophil count elevation. Conclusion: Substantial increases in bone marrow FDG uptake are rapidly induced by CSF treatments and should not be misinterpreted as diffuse bone marrow metastases.

AB - Purpose: To evaluate the effect of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) on bone marrow glucose metabolism in rodents and in patients, as assessed by 2- [fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) uptake measured directly or by positron-emission tomography (PET) scanning. Materials and Methods: Groups of three rats received either daily saline, G-CSF, or GM-CSF injections far 7 days. After treatment, FDG was injected and F-18 activities in tissues measured 1 hour later. Twenty-two breast cancer patients treated with multiagent chemotherapy were sequentially studied with PET. Eleven patients received G-CSF therapy as an adjunct to chemotherapy, while 11 received chemotherapy only. The standardized uptake value-lean (SUL) of bone marrow FDG uptake was measured and compared. Results: In rats, bone marrow F-18 activity was significantly higher in both CSF groups than in the saline group (G-CSF, 0.44 ± 0.08; GM-CSF, 0.88 ± 0.02; saline, 0.18 ± 0.02% injected dose [ID]/g · kg; P <.05), but the other normal tissues had comparable biodistributions to controls. In breast cancer patients, the FDG uptake of bone marrow did not change with chemotherapy alone; however, marrow uptake was increased after treatment with G-CSF. The dose of G-CSF and duration of treatment were correlated with the extent of increase in FDG uptake. The SUL of bone marrow was as follows: baseline, 1.56 ± 0.23; after one cycle, 3.13 ± 1.40 (P <.01); after two cycles, 2.22 ± 0.85 (P <.05); and after three cycles, 2.14 ± 0.79 (P <.05), respectively. Although the FDG uptake of bone marrow declined after G-CSF treatment was completed, it was higher than the baseline level far up to 4 weeks post-completion of G-CSF and the elevated marrow FDG uptake was sustained longer than the period of blood neutrophil count elevation. Conclusion: Substantial increases in bone marrow FDG uptake are rapidly induced by CSF treatments and should not be misinterpreted as diffuse bone marrow metastases.

UR - http://www.scopus.com/inward/record.url?scp=0031972860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031972860&partnerID=8YFLogxK

M3 - Article

C2 - 9440740

AN - SCOPUS:0031972860

VL - 16

SP - 173

EP - 180

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -